Bloomberg reports that the European Medicines Agency (EMA) has agreed to a rolling review of the marketing application for AstraZeneca (AZN -0.3%) and the University of Oxford's COVID-19 vaccine (AZD1222/ChAdOx1).
The timing of the filing should be next year since topline data from two pivotal large-scale studies will not likely be available until then.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.